Pacira BioSciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pacira BioSciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $541.53M | Feb 28, 2022 |
| FY2020 | Dec 31, 2020 | $130.97M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $117.48M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $75.51M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $105.68M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $122.42M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $104.69M | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | $102.60M | Mar 1, 2021 |
| FY2020 | Mar 31, 2019 | $91.31M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $95.12M | Feb 21, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $726.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $700.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $674.98M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $666.82M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $541.53M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $429.65M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $418.93M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $332.43M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $284.34M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $270.07M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($99.56M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $41.96M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $15.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $41.98M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $14.51M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $130.12M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($7.27M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $8.16M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($4.89M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($73.37M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $87.68M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $60.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $89.92M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $46.35M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $10.48M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $15.92M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($24.94M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($32.02M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $81.58M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $76.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $84.80M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $59.42M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $72.12M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $55.69M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $57.29M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $45.68M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $294.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $269.44M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $254.52M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $199.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $193.52M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $200.78M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $177.27M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $161.49M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $152.61M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $189.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $154.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $145.27M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $125.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $77.03M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $70.52M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $48.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $17.79M | Feb 21, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $15.16M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $30.08M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $45.87M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $37.80M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $10.16M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $14.51M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $19.27M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $24.71M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.55B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.57B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.68B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.08B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.27B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $831.07M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $689.35M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $628.37M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $391.47M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $571.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $775.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $704.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $906.19M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.34B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $654.83M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $476.12M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $368.13M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $348.89M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $172.49M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $693.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $778.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $870.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $775.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $730.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $619.69M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $354.94M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $321.23M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $279.48M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $218.98M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $163.24M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $163.24M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $145.20M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $99.55M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $99.55M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $62.04M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $55.20M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $46.74M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($199.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($206.36M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($106.80M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($148.75M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($211.90M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($253.88M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($399.40M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($388.23M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($389.14M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($346.24M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $276.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $153.30M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $104.14M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $585.58M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $99.96M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $78.23M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $132.53M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $54.13M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $35.94M | Feb 21, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $372.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $585.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $522.44M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $689.47M | Feb 29, 2024 |
| FY2016 | Dec 31, 2016 | $108.74M | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $104.04M | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $103.10M | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $98.96M | Feb 24, 2015 |
| FY2013 | Dec 31, 2012 | $25.19M | Feb 25, 2014 |
| FY2012 | Dec 31, 2011 | $25.58M | Mar 7, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 3 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 46.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 46.48M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 45.93M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 44.73M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 43.64M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 41.91M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 41.22M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 40.67M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 37.48M | Feb 28, 2018 |